MORRIS PLAINS, N.J., May 1, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the issuance of US patent 8,168,186 for additional claims for the patent family "Therapeutic using a bispecific antibody."